These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31227343)

  • 1. Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.
    Winston-McPherson GN; Xie H; Yang K; Li X; Shu D; Tang W
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2345-2348. PubMed ID: 31227343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
    Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
    Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule modulators of PCSK9 - A literature and patent overview.
    Pettersen D; Fjellström O
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1155-1160. PubMed ID: 29519739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro.
    Li L; Shen C; Huang YX; Li YN; Liu XF; Liu XM; Liu JH
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30235833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of PCSK9 inhibition and its effects beyond LDL receptors.
    Dixon DL; Trankle C; Buckley L; Parod E; Carbone S; Van Tassell BW; Abbate A
    J Clin Lipidol; 2016; 10(5):1073-80. PubMed ID: 27678423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations.
    Guarnieri F; Kulp JL; Kulp JL; Cloudsdale IS
    PLoS One; 2019; 14(12):e0225780. PubMed ID: 31805108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors.
    Lammi C; Sgrignani J; Arnoldi A; Lesma G; Spatti C; Silvani A; Grazioso G
    J Med Chem; 2019 Jul; 62(13):6163-6174. PubMed ID: 31260298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 and Hypercholesterolemia: Therapeutic Approach.
    Obradovic M; Zaric B; Sudar-Milovanovic E; Ilincic B; Stokic E; Perovic M; Isenovic ER
    Curr Drug Targets; 2018; 19(9):1058-1067. PubMed ID: 29210646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9.
    Bourbiaux K; Legrand B; Verdié P; Mallart S; Manette G; Minoletti C; Stepp JD; Prigent P; Le Bail JC; Gauzy-Lazo L; Duclos O; Martinez J; Amblard M
    J Med Chem; 2021 Aug; 64(15):10834-10848. PubMed ID: 34266235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction.
    Sun H; Wang J; Liu S; Zhou X; Dai L; Chen C; Xu Q; Wen X; Cheng K; Sun H; Yuan H
    J Chem Inf Model; 2021 Oct; 61(10):5269-5279. PubMed ID: 34553597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
    Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
    PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis.
    McClure KF; Piotrowski DW; Petersen D; Wei L; Xiao J; Londregan AT; Kamlet AS; Dechert-Schmitt AM; Raymer B; Ruggeri RB; Canterbury D; Limberakis C; Liras S; DaSilva-Jardine P; Dullea RG; Loria PM; Reidich B; Salatto CT; Eng H; Kimoto E; Atkinson K; King-Ahmad A; Scott D; Beaumont K; Chabot JR; Bolt MW; Maresca K; Dahl K; Arakawa R; Takano A; Halldin C
    Angew Chem Int Ed Engl; 2017 Dec; 56(51):16218-16222. PubMed ID: 29073340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation.
    Petersen DN; Hawkins J; Ruangsiriluk W; Stevens KA; Maguire BA; O'Connell TN; Rocke BN; Boehm M; Ruggeri RB; Rolph T; Hepworth D; Loria PM; Carpino PA
    Cell Chem Biol; 2016 Nov; 23(11):1362-1371. PubMed ID: 27746128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design.
    Sgrignani J; Fassi EMA; Lammi C; Roda G; Grazioso G
    ChemMedChem; 2020 Aug; 15(16):1601-1607. PubMed ID: 32558225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.